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Background: Measurement of biochemical markers of myocardial injury plays an 
important role in the diagnosis of cardiovascular disseases. Increase in some cardiac 
biomarkers is one of main diagnostic standard in acute myocardial infarction (AIM) 
with or without ST elevation (STEMI, NSTEMI). Recently, the European Society             
of Cardiology, the American College of Cardiology Foundation, the American Heart 
Association, and the World Heart Federation have published a consensus definition 
of myocardial infarction (AIM) that includes a detailed guideline for the assessment  
of biochemical markers in suspected AIM. The principal markers recommended in 
this setting include cardiac troponins (cTnI and cTnT) as markers of myocardial 
necrosis and myoglobin (MYO) and creatine kinase MB isoenzyme (CK-MB mass) 
quantification in the diagnosis of reinfarction. Excluding acute coronary syndromes, 
myocardial injury may be found in patients with the other cardiovascular diseases, 
during therapeutic procedures and operations (e.g. percutaneous coronary 
intervention, radiofrequency ablation etc.) or in treatment with cardiotoxic drug.  
Methods: For cardiac troponins, in last time, methods on higher analytical sentitivity, 
so called high-sensitive tests, have been rapidly developed. The armamentarium             
of cardiac markers has expanded to include several molecules that could be 
potentially useful for diagnosis of acute coronary syndromes (AKS) and are awaiting 
validation for routine clinical applications. These novel analytes include glycogen 
phosphorylase BB isoenzyme (GPBB), heart-type fatty acid-binding protein (h-FABP) 
and carbonic anhydrase III (CA III).  
Evidence Investigator biochip system (Randox) was used to measure levels selected 
cardiac biomarkers including CKMB mass, cTnI, MYO, h-FABP, CAIII and GPBB.  In 
addition, we have tested a highly sensitive cardiac troponin T     (hs-cTnT) assay for 
Elecsys 2010 analyzer (Roche). Cardiac biomarker levels were measured in cohorts 
of healthy blood donors and various patient´s groups with cardiovascular diseases 
(acute myocardial infarction, hypertrophic cardiomyopathy, cardiotoxicity                        
of chemotheraphy, radiofrequency ablation).   
Results: As expected, in AIM patients we have observed statistically significant 
increases in the serum levels of the measured cardiac biomarkers. In radiofrequency 
ablation our data indicate that procedure causes the most significant increase of 
serum hs-cTnT concentration that could be used to monitor myocardial injury.          
In hypertrophic cardiomyopathy patients, GPBB and h-FABP levels are more 
sensitive markers compare to troponin I, CKMB mass and myoglobin levels, GPBB 
level was associated with clinical parameters. Our results suggest that administration 
of chemotherapy for hematologic malignancies could be associated with myocardial 
injury manifested by increased release of GPBB from cardiomyocytes. 
Conclusion: Multianalyte biochip-based assay is applicable for biochemical 
diagnosis of acute coronary syndromes and may add valuable information to 
standard single marker assays.   
 
 
 
 
